BeiGene, Ltd. is shifting to a combination therapy strategy for its Bruton's tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib), the recently Shanghai-listed Chinese firm said.
Although the company has been studying the oncology drug as a monotherapy versus Imbruvica (ibrutinib) from Janssen Pharmaceuticals Inc./Pharmacyclics, Inc